Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brenetafusp + monoclonal antibodies + chemotherapy
- Development stage
- Unknown
- Lead developer
- Immunocore
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination regimen consisting of **brenetafusp** (IMC-F106C), a bispecific T cell receptor (ImmTAC) targeting PRAME in HLA-A*02:01-positive tumors, together with **monoclonal antibodies** (such as PD-1 inhibitors like nivolumab or pembrolizumab) and **chemotherapy**. Brenetafusp redirects cytotoxic T cells to target and kill PRAME-expressing tumor cells. Combination with monoclonal antibodies aims to further modulate immune response, and the addition of chemotherapy may enhance tumor cell susceptibility through cytotoxic effects and potentially increase antigen presentation. This multi-agent approach is being investigated in advanced/metastatic melanoma and ovarian cancer, especially in patients who are refractory or resistant to standard therapies[1][2][3][4][5].
- Other names
- PRAME ImmTAC bispecific + monoclonal antibodies + chemotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAHLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on brenetafusp + monoclonal antibodies + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brenetafusp + monoclonal antibodies + chemotherapy.